# Clinical Trials Data EGFR - Document 54

# The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors

## Clinical Trial: https://clinicaltrials.gov/study/NCT00984425

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Patients with locally advanced, recurrent or metastatic histologically confirmed malignancy refractory to available standard treatment\n\nExclusion Criteria:\n\n\* Prior treatment with Lapatinib, Sorafenib or any agents targeting EGFR (other than trastuzumab), Raf, VEGF, or VEGFR",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the exclusion criteria provided, a patient with an EGFR gene mutation would likely not be eligible for this clinical trial if they have previously received treatment with any agents targeting EGFR (other than trastuzumab). If the patient with the EGFR mutation has received such treatment, this would exclude them from participating. However, if they have not received any EGFR-targeting agents except for trastuzumab, they may still be eligible, assuming they meet other inclusion criteria.